| Literature DB >> 22174898 |
Marie-Noëlle Delyfer1, Wolfgang Raffelsberger, David Mercier, Jean-François Korobelnik, Alain Gaudric, David G Charteris, Ramin Tadayoni, Florence Metge, Georges Caputo, Pierre-Olivier Barale, Raymond Ripp, Jean-Denis Muller, Olivier Poch, José-Alain Sahel, Thierry Léveillard.
Abstract
BACKGROUND: Retinal detachment often leads to a severe and permanent loss of vision and its therapeutic management remains to this day exclusively surgical. We have used surgical specimens to perform a differential analysis of the transcriptome of human retinal tissues following detachment in order to identify new potential pharmacological targets that could be used in combination with surgery to further improve final outcome. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2011 PMID: 22174898 PMCID: PMC3235162 DOI: 10.1371/journal.pone.0028791
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Clinical characteristics of patients with retinal detachment (RD).
| Age | Sex | Prior RD surgical procedures | Total RD duration | PVR at surgery |
| 70 | M | 1 (Vitrectomy + silicone oil tamponade) | 1 week | CA2 |
| 39 | F | 1 (Vitrectomy + gas) | 3 weeks | CP2–CA2 |
| 55 | F | 1 (Vitrectomy + gas) | 1 month | CP4–CA3 |
| 73 | F | 1 (Vitrectomy + gas) | 1 month | CA2 |
| 36 | M | 1 (Vitrectomy + silicone oil tamponade) | 1 month | CP2–CA2 |
| 66 | M | No | 2 months | CP12–CA10 |
| 54 | M | 2 [(Cryotherapy + gas)/(Vitrectomy + silicone oil tamponade)] | 2 months | CP2–CA3 |
| 23 | M | No | 2 months | CP4–CA4 |
| 69 | M | 1 (Vitrectomy + silicone oil tamponade) | 3 months | CP2–CA2 |
| 65 | M | 1 (Vitrectomy + silicone oil tamponade) | 3 months | CA3 |
| 58 | M | 1 (Vitrectomy + silicone oil tamponade) | 3 months | CP2–CA2 |
| 55 | M | 2 [(Cryo + scleral buckling)/Vitrectomy + gas)] | 3 months | CP12–CA9 |
| 31 | M | No | >3 months | CP4 |
| 74 | F | No | 4 months | CP3–CA2 |
| 32 | M | 2 [(Cryo + scleral buckling)/Vitrectomy + gas)] | 6 months | CP3–CA3 |
| 59 | F | 2 [(Cryo + scleral buckling)/Vitrectomy + gas)] | 6 months | CP3–CA3 |
| 53 | M | 1 (Vitrectomy + gas) | 7 months | CP4–CA4 |
| 49 | M | 2 [(Cryo + scleral buckling)/Vitrectomy + gas)] | 1 year | CA4 |
| 30 | M | No | 1 year | CP12–CA8 |
Proliferative vitreoretinopathy (PVR) is graded using the up-dated classification of the Retina Society Terminology Committee by Machemer [22]. There are three grades describing increasing severity of the disease: A, B and C. In patients that all required retinectomy, RDs are always associated with grade C of PVR. Posterior (P) and anterior (A) location of the proliferations are specified. The extent of the abnormalities is detailed by using clock hours. Hence, CP3–CA2 means grade C of PVR with both posterior (P) and anterior (A) abnormalities extended over three (CP3, meaning ¼) and two (CA2) clock hours respectively.
Figure 1The Kit "jouRNAl" for RNA conservation.
(A) Denaturing agarose gel electrophoresis of RNAs purified from porcine retinas. Retinas were immerged in 2.4 ml of 6 M GHCl and purified: i) immediately after immersion (H0) or ii) after storage at room temperature during 72 hours (H72) or iii) after storage at room temperature during 72 hours and then at -80°C during 6 months (M6). 28 S and 18 S ribosomal RNA species have a ratio of 2 indicating the absence of RNA degradation. (B). Agarose gel electrophoresis of RT-PCR amplification products (β-actin, Rhodopsin, M-cone opsin). Similar products were obtained for the 3 samples.
Comparison of the expression measured by quantitative RT-PCR and by hybridization to array.
| Gene Name | Gene Symbol | QRT-PCR | Probeset n° | Affymetrix | |||||||
| RD/Ctrs | SE | pvalue | RD/Ctrs | SE | pvalue | ||||||
|
| |||||||||||
| ASK1 |
| 1.84 | 0.09 | <0.005 | 203836_s_at | 1.65 | 0.03 | 2.5e–5 | |||
|
| |||||||||||
| AlphaB crystallin |
| 0.91 | 0.04 | NS | 209283_at | 1.35 | 0.03 | 4.3e–3 | |||
|
| |||||||||||
| GFAP |
| 7.96 | 1.00 | <0.0005 | 203540_at | 12.49 | 0.39 | 5.4e–10 | |||
| GLAST |
| 1.38 | 0.12 | NS | 202800_at | 2.00 | 0.04 | 2.3e–8 | |||
| Glutamine synthetase |
| 0.40 | 0.02 | <0.00005 | 215001_s_at | 0.70 | 0.01 | 9.3e–8 | |||
|
| |||||||||||
| CD68 |
| 11.66 | 1.03 | <0.005 | NU | ||||||
| Alpha-smooth muscle actin |
| 8.39 | 0.32 | <0.05 | 200974_at | 8.10 | 0.44 | 2.5e–4 | |||
|
| |||||||||||
| CD4 |
| 1.82 | 0.11 | <0.05 | 203547_at | 1.72 | 0.05 | 1.6e–2 | |||
| Intercellular adhesion molecule 1 |
| 27.24 | 4.17 | <0.0005 | 202638_s_at | 17.10 | 0.77 | 3.0e–9 | |||
|
| |||||||||||
| Matrix MetalloProteinase 2 |
| 3.86 | 0.32 | <0.0005 | 201069_at | 4.65 | 0.12 | 1.0e–9 | |||
| Tissue Inhibitor Metalloproteinase 1 |
| 9.11 | 0.51 | <0.0001 | 201666_at | 9.90 | 0.23 | 1.8e–7 | |||
|
| |||||||||||
| PCNA |
| 0.26 | 0.03 | <0.0005 | 201202_at | 0.48 | 0.01 | 3.6e–8 | |||
| c-fos |
| 0.22 | 0.04 | <0.05 | 209189_at | 0.49 | 0.04 | 1.57 | |||
| Ornithine decarboxylase |
| 1.37 | 0.11 | NS | 200790_at | 1.28 | 0.02 | 3.0e–3 | |||
| Cyclin A1 |
| 0.68 | 0.10 | NS | NU | ||||||
| Cyclin D1 |
| 6.09 | <0.01 | 208712_at | 4.00 | 0.14 | 1.7e–8 | ||||
NS, non statistically significant. NU, Not used since the probesets 203507_at (CD68) and 205899_at (CCNA1) have relative expression value <10 in any condition.
Figure 2Comparison QRT-PCR/Array results.
(A) Expression of Affymetrix probesets for mRNA tested by quantitative RT-PCR. The histograms display controls (Ctrs) and retinal detachment (RD) for each specimen. The horizontal line is the average. (B) Graph displaying the Log10 of ratio retinal detachments versus controls (RD/Ctrs). CD4 and Cyclin A1 (CCNA1) were excluded from the analysis since the values were inferior to 10 in any conditions, while the cone long and middle wave opsin genes (OPN1LW and OPN1MW) were averaged since the Affymetrix probeset does not distinguish the two genes in tandem on the genome.
Figure 3Interactomic analysis of the genes identified by FDR.
The interaction between genes identified using the FDR methods. The circles on the left and on the right have been named according to their enrichment in gene ontology terms.
Enrichment scores of clusters of Gene Ontology terms for targeted identified by FDR or MI.
| Enrichment Score | Cluster description |
|
| |
| 8.77 | Immune response |
| 8.31 | Antigen processing |
| 7.23 | Response to stress |
| 3.41 | Signal transduction |
| 2.55 | Carbohydrate binding |
| 2.48 | Cell morphogenesis |
| 2.41 | Membrane |
| 2.02 | Cell death |
|
| |
| 4.58 | Antigen processing and presentation |
| 2.90 | Visual perception |
| 1.83 | Organelle outer membrane |
| 1.50 | Membrane docking |
| 1.35 | Phototransduction |
Figure 4Expression of B2M, RHO and NXNL1 in a radar graph display.
The graph has been designed using Retinobase. The controls (N1 to N19) and the retinal detached specimens (RD1 to RD19) are displayed on the left and the right of the radars respectively.
Figure 5The role of the three identified biomarkers HLA-C, PKD2L1 and SLCO4A1 as classifiers.
Expression of the three RD markers HLA-C, PKD2L1 and SLCO4A1 in the specimens. The black line represents the classes that are: controls, early, RD≤1 month, mid-term, 1>RD≤3 months and late, RD >3 months.
A Subset of down-regulated genes identified by mutual information analysis.
| Gene Name | Gene Symbol | Affymetrix | OR/NR |
| ATP-binding cassette, sub-family A, member 4 |
| 97730_at | 1.57 |
| Adducin 1 (alpha) |
| 94535_at | 1.01 |
| A kinase (PRKA) anchor protein 1 |
| 97368_at | 1.15 |
| Adaptor-related protein complex 1, gamma 1 subunit |
| 103242_at | 1.20 |
| Rho GTPase activating protein 5 |
| 92247_at | 1.22 |
| ATPase family, AAA domain containing 2B |
| 93426_at | 1.43 |
| Carbonic anhydrase XIV |
| 98079_at | 0.63 |
| Calcium channel, voltage-dependent, beta 2 subunit |
| 100757_at | 1.58 |
| Calsequestrin 1 |
| 102426_at | 0.99 |
| Dopamine receptor D4 |
| 97755_at | 1.07 |
| Estrogen-related receptor beta |
| 100301_at | 1.27 |
| Enhancer of zeste homolog 1 (Drosophila) |
| 100486_at | 1.71 |
| UDP-N-acetyl-alpha-D-galactosamine |
| 97553_at | 0.95 |
| Heat shock protein 90kDa alpha (cytosolic), class A member 1 |
| 95282_at | 1.24 |
| Kinesin family member 1B |
| 160871_at | 1.25 |
| Leucine-rich repeats and calponin homology (CH) domain containing 4 |
| 104151_at | 1.18 |
| Membrane-bound transcription factor peptidase |
| 95754_at | 0.88 |
| Myosin, light chain 6 |
| 97542_at | 1.04 |
| NADH dehydrogenase (ubiquinone) 1 alpha subcomplex |
| 160477_at | 0.95 |
| Poly(A) binding protein interacting protein 2B |
| 96158_at | 1.06 |
| Phosphodiesterase 6D |
| 160602_at | 1.32 |
| 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 |
| 98329_at | 1.44 |
| Phospholipase A2, group V |
| 101328_at | 1.17 |
| Polymerase (DNA-directed), epsilon 4 |
| 95121_at | 0.90 |
| Protein phosphatase, EF-hand calcium binding domain 2 |
| 100317_at | 1.77 |
| Protein phosphatase 1, catalytic subunit, gamma isoform |
| 101482_at | 1.21 |
| Protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform |
| 160948_at | 1.25 |
| PTC7 protein phosphatase homolog (S. cerevisiae) |
| 99503_at | 0.81 |
| PRP4 pre-mRNA processing factor 4 homolog B (yeast) |
| 102017_at | 1.29 |
| Parvalbumin |
| 96719_i_at | 0.86 |
| Renal tumor antigen MOK |
| 104166_at | 1.14 |
| Receptor accessory protein 6 |
| 96134_at | 1.65 |
| Retinal G protein coupled receptor |
| 95331_at | 0.94 |
| Ribosomal RNA processing 1 homolog B (S. cerevisiae) |
| 93130_at | 1.20 |
| S-antigen; retina and pineal gland (arrestin) |
| 94150_at | 1.16 |
| Splicing factor, arginine/serine-rich 3 |
| 101004_f_at | 1.58 |
| Solute carrier family 25 |
| 93084_at | 0.84 |
| Solute carrier family 4, sodium bicarbonate cotransporter, member 7 |
| 93471_at | 1.82 |
| Solute carrier family 6 |
| 97383_at | 1.09 |
| Serine palmitoyltransferase, long chain base subunit 2 |
| 100893_at | 1.09 |
| Synovial sarcoma, X breakpoint 2 interacting protein |
| 96723_f_at | 1.02 |
| Syntaxin binding protein 1 |
| 97983_s_at | 1.36 |
| T-complex-associated-testis-expressed 3 |
| 99134_at | 1.16 |
| Ubiquinol-cytochrome c reductase binding protein |
| 95472_f_at | 0.90 |
OR, outer retina. NR, neural retina.
Figure 6Kinetics of expression of the orthologous of a subset of the target genes in the wild-type and rd1 retina between PN1 and PN35.
(A) Pepf2, (B) Ppp3cc, (C) Slc6a6, (D) Drd4, (E) Reep6 and (F) Pde6d. PN, post-natal day.
Figure 7Dynamic of the change in expression.
(A) Relative expression of three upregulated probesets selected by FDR but ignored by MI. ICAM1: intercellular adhesion molecule 1, OSMR: oncostatin M receptor, ITGB2, integrin, beta 2. The histograms display controls (Ctrs) and retinal detachment (RD) for each specimen. The horizontal line is the average. (B) Relative expression of thee downregulated probesets selected by MI but ignored by FDR. GUCA1C: guanylate cyclase activator 1C, ABCA4: ATP-binding cassette, CNGB1: cyclic nucleotide gated channel beta 1. (C) Graph displaying the ratios retinal detachments versus the average value of controls (RD/Ctrs) for ICAM1 and OSMR. D. Graph displaying the ratios of the average value of controls versus retinal detachments versus (Ctrs/RD) for GUCA1C and ATPA4.